IP Library Granted Patent US 9,937,209
Granted Patent B2
US 9,937,209 · App. 14/941,754 · Granted Apr 10, 2018

Glycosaminoglycan compositions in combination with stem cells

Inventors: Frank D. Marcum (Lexington, KY); James Conway (Clermont, FL)
Assignee: ARTHRODYNAMIC HOLDINGS, LLC
A61K35/28A61K31/715A61K31/728A61K35/35A61K38/18A61K38/1825A61K38/1841A61K38/1875A61K38/27A61K38/30A61K45/06A61L27/26A61L27/34A61L27/3834A61L27/3852A61L27/54A61B17/064A61B17/06166A61B2017/00004A61L2300/41A61L2300/414A61L2300/426A61L2300/43A61L2400/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,937,209
App. No.
14/941,754
Granted
Apr 10, 2018
Kind
B2
Abstract

A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided.

Claims (7)

1. A method of cryopreserving isolated stem cells comprising combining isolated stem cells with a composition comprising chondroitin sulfate and hyaluronan in a container, and cryopreserving the combination in the container.

2. The method of claim 1 , wherein the composition further comprises N-acetyl D-glucosamine.

3. The method of claim 1 , wherein said chondroitin sulfate is a mixture of chondroitin 4-sulfate and chondroitin 6-sulfate.

4. The method of claim 1 , wherein the chondroitin sulfate is in a concentration of about 50-100 mg/ml.

5. The method of claim 1 , wherein the chondroitin sulfate is in a concentration of about 100 mg/ml.

6. The method of claim 1 , wherein the hyaluronan is in a concentration of about 1-5 mg/ml.

7. The method of claim 1 , wherein the hyaluronan is in a concentration of about 5 mg/ml.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2017
From: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.
To: ARTHRODYNAMIC HOLDINGS, LLC
Reel/Frame 040854/0031 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2015
From: MARCUM, FRANK D.; CONWAY, JAMES
To: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.
Reel/Frame 037044/0982 →
Continuity (3)
Continuation 13545327 · Jul 10, 2012
Continuation In Part 11766510 · Jun 21, 2007
Related Publication 20160067282A1 · Mar 10, 2016